Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era
Kehinde Osinowo,1 Fintirimam Sambo-Donga,1 Oluwaseun Ojomo,1 Segun Emmanuel Ibitoye,1 Philip Oluwayemi,1 Morounfola Okunfulure,1 Oladapo Alabi Ladipo,1 Michael Ekholuenetale1,2 1Association for Reproductive and Family Health, Trade and Convention Center, Abuja, Nigeria; 2Department of Epidemiology a...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1af77b02412d47b48f69274f5984dfb0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1af77b02412d47b48f69274f5984dfb0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1af77b02412d47b48f69274f5984dfb02021-12-02T19:17:36ZResilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era1179-1527https://doaj.org/article/1af77b02412d47b48f69274f5984dfb02021-12-01T00:00:00Zhttps://www.dovepress.com/resilient-and-accelerated-scale-up-of-subcutaneously-administered-depo-peer-reviewed-fulltext-article-OAJChttps://doaj.org/toc/1179-1527Kehinde Osinowo,1 Fintirimam Sambo-Donga,1 Oluwaseun Ojomo,1 Segun Emmanuel Ibitoye,1 Philip Oluwayemi,1 Morounfola Okunfulure,1 Oladapo Alabi Ladipo,1 Michael Ekholuenetale1,2 1Association for Reproductive and Family Health, Trade and Convention Center, Abuja, Nigeria; 2Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, NigeriaCorrespondence: Kehinde Osinowo Email osinowo.k@arfh-ng.orgBackground: Injectable contraceptives are fast becoming the method of choice among women in sub-Saharan Africa (SSA). Specifically, the subcutaneously administered depot–medroxyprogesterone acetate (DMPA-SC) is gaining traction as a convenient, private and effective method to address unmet need for family planning (FP). The objective of this study was to determine the trend in DMPA-SC use in Nigeria.Methods: Data was extracted from the National Health Management Information System (NHMIS) FP register on DMPA-SC uptake in public health facilities and through community-oriented resource providers (CORPS) in 10 Nigerian states. The linear trend model was adopted in data analysis based on lowest measure of dispersion and/or highest adjusted coefficient of determination (R2). The statistical significance was determined at 5%.Results: There was an upward trend in the use of DMPA-SC among clients who received the service through health providers, CORPS and self-injection in the 10 project states over a period of 12 months (August 2019–July 2020). In addition, the linear trend model showed that for every unit increase in months, the average number of women expected to use DMPA-SC through health providers, CORPS and self-injection will increase by 1308.3 (Yt = 3799.7 +1308.3*t), 756.73 (Yt = − 1030.8 +756.73*t) and 77.864 (Yt = − 159.7 +77.864*t) respectively. In all models, the adjusted coefficient of determination was 99.9% which showed good model fitness. The results also showed that the number of DMPA-SC clients varied across the project states with Niger (32,988) and Oyo (31,511) states reporting the highest number of clients over the period of 12 months.Conclusion: There was an increasing use of DMPA-SC and self–injection among clients over time. Health facility and community-based FP programs should be strengthened to ensure improved access to FP services.Keywords: family planning, contraceptive, Nigeria, DMPA-SC, self-injection, birth controlOsinowo KSambo-Donga FOjomo OIbitoye SEOluwayemi POkunfulure MLadipo OAEkholuenetale MDove Medical Pressarticlefamily planningcontraceptivenigeriadmpa-scself-injectionbirth controlGynecology and obstetricsRG1-991ENOpen Access Journal of Contraception, Vol Volume 12, Pp 187-199 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
family planning contraceptive nigeria dmpa-sc self-injection birth control Gynecology and obstetrics RG1-991 |
| spellingShingle |
family planning contraceptive nigeria dmpa-sc self-injection birth control Gynecology and obstetrics RG1-991 Osinowo K Sambo-Donga F Ojomo O Ibitoye SE Oluwayemi P Okunfulure M Ladipo OA Ekholuenetale M Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| description |
Kehinde Osinowo,1 Fintirimam Sambo-Donga,1 Oluwaseun Ojomo,1 Segun Emmanuel Ibitoye,1 Philip Oluwayemi,1 Morounfola Okunfulure,1 Oladapo Alabi Ladipo,1 Michael Ekholuenetale1,2 1Association for Reproductive and Family Health, Trade and Convention Center, Abuja, Nigeria; 2Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, NigeriaCorrespondence: Kehinde Osinowo Email osinowo.k@arfh-ng.orgBackground: Injectable contraceptives are fast becoming the method of choice among women in sub-Saharan Africa (SSA). Specifically, the subcutaneously administered depot–medroxyprogesterone acetate (DMPA-SC) is gaining traction as a convenient, private and effective method to address unmet need for family planning (FP). The objective of this study was to determine the trend in DMPA-SC use in Nigeria.Methods: Data was extracted from the National Health Management Information System (NHMIS) FP register on DMPA-SC uptake in public health facilities and through community-oriented resource providers (CORPS) in 10 Nigerian states. The linear trend model was adopted in data analysis based on lowest measure of dispersion and/or highest adjusted coefficient of determination (R2). The statistical significance was determined at 5%.Results: There was an upward trend in the use of DMPA-SC among clients who received the service through health providers, CORPS and self-injection in the 10 project states over a period of 12 months (August 2019–July 2020). In addition, the linear trend model showed that for every unit increase in months, the average number of women expected to use DMPA-SC through health providers, CORPS and self-injection will increase by 1308.3 (Yt = 3799.7 +1308.3*t), 756.73 (Yt = − 1030.8 +756.73*t) and 77.864 (Yt = − 159.7 +77.864*t) respectively. In all models, the adjusted coefficient of determination was 99.9% which showed good model fitness. The results also showed that the number of DMPA-SC clients varied across the project states with Niger (32,988) and Oyo (31,511) states reporting the highest number of clients over the period of 12 months.Conclusion: There was an increasing use of DMPA-SC and self–injection among clients over time. Health facility and community-based FP programs should be strengthened to ensure improved access to FP services.Keywords: family planning, contraceptive, Nigeria, DMPA-SC, self-injection, birth control |
| format |
article |
| author |
Osinowo K Sambo-Donga F Ojomo O Ibitoye SE Oluwayemi P Okunfulure M Ladipo OA Ekholuenetale M |
| author_facet |
Osinowo K Sambo-Donga F Ojomo O Ibitoye SE Oluwayemi P Okunfulure M Ladipo OA Ekholuenetale M |
| author_sort |
Osinowo K |
| title |
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| title_short |
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| title_full |
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| title_fullStr |
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| title_full_unstemmed |
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era |
| title_sort |
resilient and accelerated scale-up of subcutaneously administered depot–medroxyprogesterone acetate in nigeria (rasudin): a mid-line study in covid-19 era |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/1af77b02412d47b48f69274f5984dfb0 |
| work_keys_str_mv |
AT osinowok resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT sambodongaf resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT ojomoo resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT ibitoyese resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT oluwayemip resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT okunfulurem resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT ladipooa resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era AT ekholuenetalem resilientandacceleratedscaleupofsubcutaneouslyadministereddepotndashmedroxyprogesteroneacetateinnigeriarasudinamidlinestudyincovid19era |
| _version_ |
1718376899791552512 |